UPC APP 56246/2024

Vor dem UPC: GlaxoSmithKline Biologicals SA (20 Verfahren)·Pfizer Group (31 Verfahren)

• 2024-12-03
  Preliminary objectionÖffentlich

  Zusammenfassung: The Milan Central Division rejected GlaxoSmithKline Biologicals S.A.'s preliminary objection (R. 19 RoP) in the revocation action UPC_CFI_476/2024 (EP 4 183 412 — a vaccine-related patent owned by GSK). GSK argued that a parallel infringement action by Pfizer before the Düsseldorf Local Division challenged the Central Division's competence over the revocation action. The Court held that the infringement action appeared inadmissible when lodged (filed on 5 August 2024, before the patent was granted on 14 August 2024) and therefore could not challenge the Central Division's competence over the revocation action under Art. 33 UPCA. The request for a hearing before deciding the preliminary objection was also rejected.

  Rechtsfragen anzeigen (4)

  • Preliminary objection under R. 19 RoP — competence of Central Division
  • Admissibility of infringement action filed before patent grant
  • Art. 33 UPCA — relationship between infringement action and Central Division revocation jurisdiction
  • Parallel proceedings and lis pendens

• E5F84BB34BE6B6DCC0F5EB99378AB579_en.pdf2024-12-03EN